tiprankstipranks
Advertisement
Advertisement
Keymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
PremiumCompany AnnouncementsKeymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials
1M ago
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
Premium
Company Announcements
Keymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall
1M ago
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
Premium
Company Announcements
Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
2M ago
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
PremiumMarket NewsM&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
5M ago
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
Premium
Company Announcements
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
5M ago
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
Premium
Company Announcements
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
5M ago
Keymed Biosciences Announces Successful AGM Resolutions
PremiumCompany AnnouncementsKeymed Biosciences Announces Successful AGM Resolutions
1y ago
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
Premium
Company Announcements
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
1y ago
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
Premium
Company Announcements
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100